血浆置换治疗血栓性血小板减少性紫癜临床疗效的观察被引量：6

Therapeutic plasma exchange in the treatment of thrombotic thrombocytopenic purpura

导出

摘要目的观察血浆置换治疗血栓性血小板减少性紫癜的临床疗效。方法回顾分析2013年1月—2018年6月本院14例确诊为血栓性血小板减少性紫癜患者的临床特征及进行血浆置换治疗后的疾病转归情况,分析血浆置换治疗过程中不良反应发生情况。结果 14例血栓性血小板减少性紫癜患者共进行了47次血浆置换,经过血浆置换治疗后10例患者病情好转恢复出院,血浆置换治疗血栓性血小板减少性紫癜患者的总有效率为71.4%。47次血浆置换术中共发生了3次不良反应,其不良反应发生率为6.4%。结论血浆置换是治疗血栓性血小板减少性紫癜的有效方法,患者一旦确诊或高度怀疑为血栓性血小板减少性紫癜时需尽早开始血浆置换治疗。 Objective To investigate the clinical effect of therapeutic plasma exchange for the treatment of patients with thrombotic thrombocytopenic purpura(TTP).Methods The clinical profiles of 14 patients with TTP and their outcome after plasma exchange in our hospital from January 2013 to June 2018 were analyzed retrospectively.Results In 14 TTP patients,47 plasma exchange procedures were performed.Ten of 14(71.4%)patients demonstrated a good response to plasma exchange therapy and were discharged from hospital with complete remission.Three adverse reactions occurred in 47 procedures,with the incidence of adverse reactions of 6.4%.Conclusion Plasma exchange is effective for treatment of TTP.Once the patient was diagnosed or highly suspected as TTP,plasma exchange should be initiated as soon as possible.

作者朱帮强卞茂红刘淑均闻慧琴杨鹏卫玉芝叶冬青 ZHU Bangqiang;BIAN Maohong;LIU Shujun;WEN Huiqin;YANG Peng;WEI Yuzhi;YE Dongqing(Department of Blood Transfusion,the First Affiliated Hospital of Anhui Medical University,Hefei 2300221 China;Department of Epidemiology and Biostatistics,School of Public Health,Anhui Medical University,Anhui Province Key Laboratory of Major Autoimmune Diseases)

机构地区安徽医科大学第一附属医院输血科安徽医科大学公共卫生学院流行病与卫生统计学系重大自身免疫性疾病安徽省重点实验室

出处《中国输血杂志》 CAS 2019年第4期358-361,共4页 Chinese Journal of Blood Transfusion

关键词血栓性血小板减少性紫癜血浆置换不良反应 thrombotic thrombocytopenic purpura plasma exchange adverse reactions

分类号 R457.14 [医药卫生—治疗学] R558.2 [医药卫生—血液循环系统疾病]

引文网络
相关文献

参考文献3

1张军,顾健.血栓性血小板减少性紫癜发病机制及治疗进展[J].临床血液学杂志,2016,29(1):73-76. 被引量：12
2无,阮长耿,余自强.血栓性血小板减少性紫癜诊断与治疗中国专家共识（2012年版）[J].中华血液学杂志,2012,33(11):983-984. 被引量：120
3杨俊龙,肖洁,彭涛,杨鑫,黎欢.血浆置换治疗血栓性血小板减少性紫癜2例报告[J].中国输血杂志,2017,30(11):1293-1295. 被引量：7

二级参考文献37

1Sinkovits G,Prohaszka Z.Update on the role of the complement system in the pathogenesis of thrombotic microangiopathies[J].Prilozi,2014,35:115-122.
2Motto DG,Chauhan AK,Zhu G,et al.Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice[J].J Clin Invest,2005,115:2752-2761.
3Tersteeg C,De Maat S,De Meyer SF,et al.Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy[J].Circulation,2014,129:1320-1331.
4Kremer Hovinga JA,Lammle B.Role of ADAMTS13in the pathogenesis,diagnosis,and treatment of thrombotic thrombocytopenic purpura[J].Hematology Am Soc Hematol Educ Program,2012,2012:610-616.
5Pos W,Luken BM,Sorvillo N,et al.Humoral immune response to ADAMTS13 in acquired thrombotic thrombocytopenic purpura[J].J Thromb Haemost,2011,9:1285-1291.
6Kremer Hovinga JA,Vesely SK,Terrell DR,et al.Survival and relapse in patients with thrombotic thrombocytopenic purpura[J].Blood,2010,115:1500-1511;quiz 1662.
7George JN.How I treat patients with thrombotic thrombocytopenic purpura:2010[J].Blood,2010,116:4060-4069.
8Jacob S,Dunn BL,Qureshi ZP,et al.Ticlopidine-,clopidogrel-,and prasugrel-associated thrombotic thrombocytopenic purpura:a 20-year review from the Southern Network on Adverse Reactions(SONAR)[J].Semin Thromb Hemost,2012,38:845-853.
9Coppo P,Busson M,Veyradier A,et al.HLA-DRB1*11:a strong risk factor for acquired severe ADAMTS13 deficiency-related idiopathic thrombotic thrombocytopenic purpura in Caucasians[J].J Thromb Haemost,2010,8:856-859.
10Scully M,Brown J,Patel R,et al.Human leukocyte antigen association in idiopathic thrombotic thrombocytopenic purpura:evidence for an immunogenetic link[J].J Thromb Haemost,2010,8:257-262.